Assessing People's Hospital Outpatient Appointment Preferences in the United Kingdom

November 3, 2020 updated by: Kelly Ann Schmidtke, University of Warwick
The sustainability of the United Kingdom's National Health Service's (NHS) is threatened immediately by Covid-19 and continually by an increasing prevalence of long-conditions that cannot be cured but can be maintained. Shifting traditional face-to-face outpatient appointments to remote video consultations may help the NHS continue to serve patients efficiently. While much research has examined healthcare providers' attitudes and beliefs about remote video consultations, less has attempted to understand how NHS service providers should invite patients to attend them. The present study examines how the framing of an invitation to attend a hospital outpatient appointment by video influences the proportion of people who agree to attend by video. It also explores some of the barriers and facilitators people may experience to attending appointments by video across diagnostic complexities and age groups. The results of this study should help hospitals better present patients with the option to attend video consultations where appropriate, and provide support to mitigate common barriers to people's willingness to give video consultations a go.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
1481

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United Kingdom
    • West Midlands
      • Coventry, West Midlands, United Kingdom, CV4 7HL
        • Kelly Schmidtke

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

All participants will:

  • be 18 years old or older;
  • be resident in the United Kingdom; and
  • indicate having been diagnosed with a chronic diseases such as diabetes, heart disease, stroke etc.

Exclusion Criteria:

  • be less than 18 years old;
  • not be resident in the United Kingdom; and
  • not indicate having been diagnosed with a chronic diseases such as diabetes, heart disease, stroke etc.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Video Default

The case and response options participants in this group will be asked to consider is provided below.

Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend your next consultation by video.

Consider each of the response options below, and select the one that best describes how you would respond to your clinician.

A) Yes, I would be happy to attend a video consultation. B) If possible, I would rather attend the appointment in person.
Behavioral: Video Default

The case and response options participants in this group will be asked to consider is provided below.

Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend your next consultation by video.

Consider each of the response options below, and select the one that best describes how you would respond to your clinician.

A) Yes, I would be happy to attend a video consultation. B) If possible, I would rather attend the appointment in person.
Experimental: In-Person Default

The case and response options participants in this group will be asked to consider is provided below.

Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend your next consultation in person.

Consider each of the response options below, and select the one that best describes how you would respond to your clinician.

A) Yes, I would be happy to attend an in-person consultation. B) If possible, I would rather attend the appointment by video.
Behavioral: In-Person Default

The case and response options participants in this group will be asked to consider is provided below.

Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend your next consultation in person.

Consider each of the response options below, and select the one that best describes how you would respond to your clinician.

A) Yes, I would be happy to attend an in-person consultation. B) If possible, I would rather attend the appointment by video.
Experimental: Active Choice

The case and response options participants in this group will be asked to consider is provided below.

Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend a consultation by video or in person.

Consider each of the response options below, and select the one that best describes how you would respond to your clinician.

A) I would prefer a video consultation. B) I would prefer an in-person consultation.
Behavioral: Active Choice

The case and response options participants in this group will be asked to consider is provided below.

Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend a consultation by video or in person.

Consider each of the response options below, and select the one that best describes how you would respond to your clinician.

A) I would prefer a video consultation. B) I would prefer an in-person consultation.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Response to the outpatient invitation
Time Frame: One day
Participants responses will indicate whether they would prefer a video or in-person appointment.
One day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of Warwick

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Kelly A Schmidtke, PhD, University of Warwick

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
September 11, 2020

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
October 31, 2020

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
October 31, 2020

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 24, 2020

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 28, 2020

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
September 2, 2020

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
November 5, 2020

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 3, 2020

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
November 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • BSREC 110/19-20

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

The anonymised individual level data may be made available upon reasonable request within 10 years of the project being published in an academic jourhnal or may be published with an article if required by the journal.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings